Login to Your Account



Clinic Roundup


Monday, April 9, 2012
• Tonix Pharmaceuticals Holding Corp., of New York, completed a trial of TNX-102 for fibromyalgia syndrome. The pharmacokinetic study suggested the drug could have similar benefits as low-dose cyclobenzaprine in fibromyalgia patients. That is the first of a number of formulations that the company will be testing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription